Description of Invention: The NIH announces a new technology that relates to compounds that possess potent androgenic activity. These compounds include 7-alpha, 11-beta-dimethyl-17-beta-hydroxyestra-4,14-dien-3-one and 17 esters thereof, and 7-alpha,11-beta-dimethyl-17-beta-hydroxyestra-4-en-3-one 17-undecanoate. These compounds offer a potential therapeutic benefit in the treatment of hypogonadism, regardless of cause, as an adjuvant in hormone replacement therapy for both men and women and for androgen stimulation of anabolism in a broad spectrum of disease entities involving debilitation.
These compounds exhibit both oral and parenteral androgenic activity. Oral activity appears greater than that of methyltestosterone. Parenteral activity as an aqueous suspension is substantially longer than that produced by testosterone enanthate or testosterone cypionate. Since these compounds lack a 17-alkyl moiety, they are expected to show less hepatotoxicity upon oral administration. Claims in this patent application are drawn to the new androgenic compounds themselves, their method of preparation, pharmaceutical formulations containing the new androgens and their utility and use in a wide spectrum of therapeutic applications.
Related Technologies: EIR, Reference No. E-181-2004/0 US, Application No. 60/650,376 filed 04 Feb 2005, Reference No. E-181-2004/0 US, Application No. 11/815,532 filed 03 Aug 2007, Reference No. E-181-2004/0
Portfolios: Gene Based Therapies Gene Based Therapies - Therapeutics Internal Medicine Internal Medicine - Therapeutics
For Additional Information Please Contact: Tara Kirby Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: tk200h@nih.gov Phone: 301-435-4426 Fax: 301-402-0220
Description of Invention:
The NIH announces a new technology that relates to compounds that possess potent androgenic activity. These compounds include 7-alpha, 11-beta-dimethyl-17-beta-hydroxyestra-4,14-dien-3-one and 17 esters thereof, and 7-alpha,11-beta-dimethyl-17-beta-hydroxyestra-4-en-3-one 17-undecanoate. These compounds offer a potential therapeutic benefit in the treatment of hypogonadism, regardless of cause, as an adjuvant in hormone replacement therapy for both men and women and for androgen stimulation of anabolism in a broad spectrum of disease entities involving debilitation.
These compounds exhibit both oral and parenteral androgenic activity. Oral activity appears greater than that of methyltestosterone. Parenteral activity as an aqueous suspension is substantially longer than that produced by testosterone enanthate or testosterone cypionate. Since these compounds lack a 17-alkyl moiety, they are expected to show less hepatotoxicity upon oral administration. Claims in this patent application are drawn to the new androgenic compounds themselves, their method of preparation, pharmaceutical formulations containing the new androgens and their utility and use in a wide spectrum of therapeutic applications.
Inventors:
Richard P Blye (NICHD)
Patent Status:
HHS, Reference No. E-069-2000/2
HHS, Reference No. E-069-2000/3
US, , Patent No. 7,196,074, Issued 27 Mar 2007
US, Application No. 12/184,600 filed 01 Aug 2008
PCT, Application No. PCT/US01/10293 filed 30 Mar 2001
Related Technologies:
EIR, Reference No. E-181-2004/0
US, Application No. 60/650,376 filed 04 Feb 2005, Reference No. E-181-2004/0
US, Application No. 11/815,532 filed 03 Aug 2007, Reference No. E-181-2004/0
Portfolios:
Gene Based Therapies
Gene Based Therapies - Therapeutics
Internal Medicine
Internal Medicine - Therapeutics
For Additional Information Please Contact:
Tara Kirby Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: tk200h@nih.gov
Phone: 301-435-4426
Fax: 301-402-0220
Ref No: 658
Updated: 02/2008